Clivi aims to become the Livongo of Latin America for diabetes management

Date:

Mexico-based diabetes management startup, Clivi, has secured $10 million in seed funding to help tackle diabetes in Latin America, where there are more than 40 million adults with the condition. Clivi aims to offer a personalised, comprehensive and technological approach to diabetes healthcare delivery, with a focus on connecting patients with endocrinologists, nutritionists and psychologists and enabling users to access monitoring and treatment plans via their communication channel of choice, such as WhatsApp. The company also provides all necessary supplies and medication, and offers health plans starting from $40 per month. Clivi’s digital clinic and diabetes remote monitoring service has already helped thousands of patients, with 94% achieving diabetes control within six months of joining the platform.

See also  China ChatGPT Bans Users for Comparing President Xi Jinping to Winnie the Pooh

Frequently Asked Questions (FAQs) Related to the Above News

What is Clivi?

Clivi is a Mexico-based diabetes management startup that offers a personalised, comprehensive and technological approach to diabetes healthcare delivery.

What is the goal of Clivi?

The goal of Clivi is to tackle the issue of diabetes in Latin America, where there are more than 40 million adults with the condition.

What services does Clivi offer?

Clivi offers a range of services, including connecting patients with endocrinologists, nutritionists and psychologists and enabling users to access monitoring and treatment plans via their communication channel of choice, such as WhatsApp. The company also provides all necessary supplies and medication and offers health plans starting from $40 per month.

How successful has Clivi been so far?

Clivi's digital clinic and diabetes remote monitoring service has already helped thousands of patients, with 94% achieving diabetes control within six months of joining the platform.

How much funding has Clivi secured?

Clivi has secured $10 million in seed funding to help further its mission of tackling diabetes in Latin America.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Advait Gupta
Advait Gupta
Advait is our expert writer and manager for the Artificial Intelligence category. His passion for AI research and its advancements drives him to deliver in-depth articles that explore the frontiers of this rapidly evolving field. Advait's articles delve into the latest breakthroughs, trends, and ethical considerations, keeping readers at the forefront of AI knowledge.

Share post:

Subscribe

Popular

More like this
Related

New Nothing Ear Buds Revolutionize Sound Quality and AI Integration

Revolutionize your audio experience with Nothing's new Ear and Ear (a) earbuds, offering premium sound quality and AI integration.

Nothing Launches Highly-Anticipated TWS Earbuds at Unbeatable Prices

Discover Nothing's highly-anticipated TWS Earbuds with ChatGPT integration, exceptional sound quality, and unbeatable prices. Shop now!

DALL-E 2 Sunset: How AI Art Revolution Ended – An Inside Story

Discover the inside story of the end of AI art revolution with DALL-E 2 Sunset. Learn about OpenAI's decision and the impact on artists and tech enthusiasts.

Nvidia vs. Amazon: The AI Stock Showdown

Investors, choose wisely in the AI sector with Nvidia vs. Amazon - find out which company is the more attractively valued stock to capitalize on AI's growth.